Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05068388 | Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density | PHASE2 | COMPLETED | 240 | — | — | Dec 21, 2021 | Mar 12, 2026 | May 20, 2026 | 1 | Sweden |
Change from baseline
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | oral capsule |
| 1 mg (Z)-endoxifen | EXPERIMENTAL | oral capsule |
| 2 mg (Z)-endoxifen | EXPERIMENTAL | oral capsule |
| Name | Type | Description |
|---|---|---|
| Z-Endoxifen | DRUG | Z-Endoxifen |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Premenopausal women (defined as having at least one menstruation during the prior 12 months; women with an intrauterine device are considered premenopausal if \<52 years) 2. Women of childbearing potential using a highly effective method of birth control\* throughout the stud...